---
title: 'Eli Lilly + Innovent Biologics, Agios, TC Biopharm, Blue Water Vaccines, Meihua'
type: 'episode'
url: 'https://doc.social/episodes/eli-lilly-innovent-biologics-agios-tc-biopharm-blue-water-vaccines-meihua'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-02-22'
audio: 'unavailable — the host retired the file'
---

# Eli Lilly + Innovent Biologics, Agios, TC Biopharm, Blue Water Vaccines, Meihua

The PD1 that lost, biopharma earns FDA approval, and the Biotech market is cool not dead Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesEli Lilly + Innovent BiologicsAgiosTC BiopharmBlue Water VaccinesMeihua About the Sh…

## Summary

The PD1 that lost, biopharma earns FDA approval, and the Biotech market is cool not dead

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[Eli Lilly + Innovent Biologics
](https://pharmaphorum.com/news/fda-wont-review-lillys-pd-1-antibody-based-on-chinese-data-alone/)[Agios](https://www.biospace.com/article/releases/agios-announces-fda-approval-of-pyrukynd-mitapivat-as-first-disease-modifying-therapy-for-hemolytic-anemia-in-adults-with-pyruvate-kinase-deficiency/?s=74)
[TC Biopharm
](https://www.biospace.com/article/releases/tc-biopharm-announces-closing-of-17-5-million-initial-public-offering/?keywords=TC+Biopharm)[Blue Water Vaccines
](https://www.biospace.com/article/releases/blue-water-vaccines-announces-pricing-of-approximate-20m-initial-public-offering/?keywords=Blue+Water+Vaccines)[Meihua](https://www.biospace.com/article/releases/meihua-international-medical-technologies-co-ltd-announces-pricing-of-36-000-000-initial-public-offering/?keywords=Meihua)

**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.